Yasser Gaber Abdelhafez

Dr. Yasser Gaber Abdelhafez

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
KCKevin J. Chung
Kevin J. Chung
YAYasser Gaber Abdelhafez
Yasser Gaber Abdelhafez
BSBenjamin A. Spencer
Benjamin A. Spencer
TJTerry Jones
Terry Jones
QTQuyen Tran
Quyen Tran
GWGuobao Wang
Guobao Wang
Neuroimaging of blood-brain barrier permeability has been instrumental in identifying its broad involvement in neurological and systemic diseases. However, current methods evaluate the blood-brain barrier mainly as a structural barrier. Here we developed a non-invasive positron emission tomography method in humans to measure the blood-brain barrier permeability of molecular radiotracers that cross the blood-brain barrier through its molecule-specific transport mechanism. Our method uses high-temporal resolution dynamic imaging and kinetic modeling for multiparametric imaging and quantification of the blood-brain barrier permeability-surface area product of molecular radiotracers. We show, in humans, our method can resolve blood-brain barrier permeability across three radiotracers and demonstrate its utility in studying brain aging and brain-body interactions in metabolic dysfunction-associated steatotic liver inflammation. Our method opens new directions to effectively study the molecular permeability of the human blood-brain barrier in vivo using the large catalogue of available molecular positron emission tomography tracers.

13 October 2023 in Science Advances
Verified
Journal Article
Open access
NONegar Omidvari
Negar Omidvari
TJTerry Jones
Terry Jones
PPPat M. Price
Pat M. Price
AFApril L. Ferre
April L. Ferre
JLJacqueline Lu
Jacqueline Lu
SCSimon R. Cherry
Simon R. Cherry
With most of the T cells residing in the tissue, not the blood, developing noninvasive methods for in vivo quantification of their biodistribution and kinetics is important for studying their role in immune response and memory. This study presents the first use of dynamic positron emission tomography (PET) and kinetic modeling for in vivo measurement of CD8 + T cell biodistribution in humans. A 89 Zr-labeled CD8-targeted minibody ( 89 Zr-Df-Crefmirlimab) was used with total-body PET in healthy individuals ( N = 3) and coronavirus disease 2019 (COVID-19) convalescent patients ( N = 5). Kinetic modeling results aligned with T cell–trafficking effects expected in lymphoid organs. Tissue-to-blood ratios from the first 7 hours of imaging were higher in bone marrow of COVID-19 convalescent patients compared to controls, with an increasing trend between 2 and 6 months after infection, consistent with modeled net influx rates and peripheral blood flow cytometry analysis. These results provide a promising platform for using dynamic PET to study the total-body immune response and memory.

19 May 2022 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
YAYasser Gaber Abdelhafez
Yasser Gaber Abdelhafez
SRSiba P. Raychaudhuri
Siba P. Raychaudhuri
DMDario Mazza
Dario Mazza
SSSoumajyoti Sarkar
Soumajyoti Sarkar
HHHeather L. Hunt
Heather L. Hunt
ACAbhijit J. Chaudhari
Abhijit J. Chaudhari
Autoimmune inflammatory arthritides (AIA), such as psoriatic arthritis (PsA) and rheumatoid arthritis (RA), are chronic systemic conditions that affect multiple joints of the body. Recently, total-body (TB) PET/CT scanners have become available that exhibit superior technical characteristics (total-body coverage, geometric sensitivity) that could benefit AIA evaluation, compared to conventional PET/CT systems. The objectives of this work were to (1) assess the performance of an ultra-low-dose, 18F-FDG TB-PET/CT acquisition protocol for evaluating systemic joint involvement in AIA; and (2) report the association of TB-PET/CT measures with joint-by-joint rheumatologic examination and standardized rheumatologic outcome measures. Methods: Thirty participants (24 with AIA and 6 with osteoarthritis (OA)), were prospectively enrolled in this single-center, observational study. All participants underwent a TB-PET/CT scan for 20 min starting at 40 min after intravenous injection of 78.1±4.7 MBq of 18F-FDG. Qualitative and quantitative evaluation of 18F-FDG uptake and joint involvement were performed from the resulting images and compared with the rheumatologic assessments. Results: TB-PET/CT enabled the visualization of 18F-FDG uptake at joints of the entire body, including those of the hands and feet, in a single bed position, and in the same phase of radiotracer uptake. A range of pathologies consistent with AIA (and non-AIA in the OA group) were visualized, and the feasibility of extracting PET measures from joints examined by rheumatologic assessments was demonstrated. Out of 1997 evaluable joints, there was concordance between TB-PET qualitative assessments and joint-by-joint rheumatologic evaluation in the AIA and non-AIA cohorts for 69.9% and 91.1% joints, respectively, while an additional 20.1% and 8.8% joints, respectively, deemed negative on rheumatologic examination showed PET-positivity. On the other hand, 10.0% and 0% joints in the AIA and non-AIA cohorts, respectively, were positive on rheumatologic evaluation but negative on TB-PET. Quantitative measures from TB-PET in the AIA cohort demonstrated a moderate to strong correlation (Spearman9s ρ=0.53-0.70, p<0.05) with the rheumatologic outcome measures. Conclusion: Systemic joint evaluation in AIA (and non-AIA) is feasible with a TB-PET/CT system and an ultra-low-dose protocol. Our results provide the foundation for future larger studies to evaluate the possible improvements in AIA joint assessment via the TB-PET/CT technology.

22 January 2020 in Skeletal Radiology
Verified
Journal Article
Closed access
PDF file
LNLorenzo Nardo
Lorenzo Nardo
YAYasser Gaber Abdelhafez
Yasser Gaber Abdelhafez
FAFrancesco Acquafredda
Francesco Acquafredda
SSSilvia Schirò
Silvia Schirò
AWAndrew L. Wong
Andrew L. Wong
TLThomas M. Link
Thomas M. Link

1 May 2016 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
ATAhmed Tawakol
Ahmed Tawakol
YAYasser Gaber Abdelhafez
Yasser Gaber Abdelhafez
AOAmr Osama
Amr Osama
EHEmad Hamada
Emad Hamada
SRSherif El Refaei
Sherif El Refaei
The aim of this study was to evaluate the diagnostic performance of combined fluorine-18 fluorodeoxyglucose (F-FDG) PET/contrast-enhanced computed tomography (Ce-CT) in comparison with Ce-CT alone for the detection of residual/recurrent tumor after initial treatment of malignant ovarian tumors. The study prospectively recruited 111 patients with a clinical suspicion of ovarian tumor recurrence. Each patient underwent F-FDG PET/computed tomography (CT) with low-dose CT, followed immediately by Ce-CT. Study-based analyses for a total of 136 scans were carried out. For each study, 11 subsites were assessed on a four-point score (score 0=definitely benign, score 1=probably benign, score 2=probably malignant, and score 3=definitely malignant). The subsites were collectively categorized into four groups: local tumor site, peritoneum, pelvi-abdominal lymph nodes, and other sites (e.g. liver, lung, bone, brain, etc). The final diagnosis of disease status was made on subsequent follow-up by conventional imaging (CT/MRI), F-FDG PET/CT, or histopathology whenever possible. Of the 136 studies evaluated, 97 (71%) studies had recurrent/residual disease and 39 (29%) studies were disease free on the basis of the final diagnosis. F-FDG PET/Ce-CT and Ce-CT had a sensitivity, specificity, negative predictive value, positive predictive value, and accuracy of 96 versus 84%, 92 versus 59%, 90 versus 59%, 97 versus 84%, and 95 versus 76%, respectively. F-FDG PET/Ce-CT was significantly more sensitive, specific, and accurate compared with Ce-CT, with P-values of 0.002, 0.001, and less than 0.0001, respectively. Site-based analyses also showed significant differences. CombinedF-FDG PET/Ce-CT significantly outperforms Ce-CT alone in the post-treatment detection of malignant ovarian tumors.

26 February 2021 in Veterinary Radiology & Ultrasound
Verified
Journal Article
Closed access
PDF file
MWMason W. Wanamaker
Mason W. Wanamaker
KVKaren Vernau
Karen Vernau
STSandra L. Taylor
Sandra L. Taylor
DCDerek Cissell
Derek Cissell
YAYasser Gaber Abdelhafez
Yasser Gaber Abdelhafez
AZAllison L. Zwingenberger
Allison L. Zwingenberger